Literature DB >> 3734476

Topical treatment of cutaneous leishmaniasis.

J El-On, R Livshin, Z Even-Paz, D Hamburger, L Weinrauch.   

Abstract

Sixty-seven patients, 19 females and 48 males, 4-66 years old, suffering from lesions of cutaneous leishmaniasis were treated topically with an ointment comprising 15% paromomycin sulfate and 12% methylbenzethonium chloride in white soft paraffin (P-ointment, U.K. patent GB117237A). After 10 days of treatment, twice daily, the lesions in 72% of the treated patients were free of parasites, 15% became free within an additional 20 days, without further treatment, and 13% failed to respond. Pigmentation developed in 18% of the treated lesions and inflammation of varying degree was associated with the treatment. These developments did not affect the clinical healing process which was generally completed in a period of 10-30 days after termination of treatment. In addition, 94% of the treated lesions healed with little or no scarring. No adverse clinical or laboratory side effects were observed except for a burning sensation at the site of treatment. Parasites isolated from patients who failed to respond to topical treatment were found to be susceptible to PR-MBCl in both in vitro infected macrophages and in vivo in experimentally infected BALB/c mice.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734476     DOI: 10.1111/1523-1747.ep12696697

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

Review 1.  Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Authors:  Shyam Sundar; Neha Agrawal; Bhawana Singh
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-17       Impact factor: 4.481

2.  Amine-Linked Flavonoids as Agents Against Cutaneous Leishmaniasis.

Authors:  Chin-Fung Chan; Zhen Liu; Iris L K Wong; Xianliang Zhao; Zaofeng Yang; Jiale Zheng; Marianne M Lee; Michael K Chan; Tak Hang Chan; Larry M C Chow
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

3.  Herbicides to curb human parasitic infections: in vitro and in vivo effects of trifluralin on the trypanosomatid protozoans.

Authors:  M M Chan; M Grogl; C C Chen; E J Bienen; D Fong
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

4.  Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model.

Authors:  Hervé Lecoeur; Pierre Buffet; Gloria Morizot; Sophie Goyard; Ghislaine Guigon; Geneviève Milon; Thierry Lang
Journal:  PLoS Negl Trop Dis       Date:  2007-11-28

5.  Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis.

Authors:  Diana Berenguer; Lilian Sosa; Magdalena Alcover; Marcella Sessa; Lyda Halbaut; Carme Guillén; Roser Fisa; Ana Cristina Calpena-Campmany; Cristina Riera
Journal:  Pharmaceutics       Date:  2019-11-15       Impact factor: 6.321

Review 6.  Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.

Authors:  Marium Azim; Saeed Ahmad Khan; Saleem Ullah; Shafiq Ullah; Syed Ishtiaq Anjum
Journal:  PLoS Negl Trop Dis       Date:  2021-03-03

7.  Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.

Authors:  Dae Hyun Kim; Hye Jin Chung; Joachim Bleys; Reza F Ghohestani
Journal:  PLoS Negl Trop Dis       Date:  2009-02-17

8.  WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.

Authors:  Afif Ben Salah; Pierre A Buffet; Gloria Morizot; Nathalie Ben Massoud; Amor Zâatour; Nissaf Ben Alaya; Nabil Bel Haj Hamida; Zaher El Ahmadi; Matthew T Downs; Philip L Smith; Koussay Dellagi; Max Grögl
Journal:  PLoS Negl Trop Dis       Date:  2009-05-05

9.  Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul.

Authors:  Ahmad Fawad Jebran; Ulrike Schleicher; Reto Steiner; Pia Wentker; Farouq Mahfuz; Hans-Christian Stahl; Faquir Mohammad Amin; Christian Bogdan; Kurt-Wilhelm Stahl
Journal:  PLoS Negl Trop Dis       Date:  2014-02-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.